RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) (“the Company” or
“RegeneRx”) today announced that it has received a Notice of Allowance
for a second U.S. patent for treating central nervous system injuries
and disorders using Thymosin beta 4 (Tβ4) to regenerate damaged tissue.
In this case, the patent will be for the treatment of patients suffering
a stroke. Researchers at the Henry Ford Hospital in Detroit, Michigan,
discovered Tβ4’s effects in animal studies performed under a Material
Transfer Agreement between the Institution and RegeneRx. RegeneRx has
received a license to the intellectual property. The patent will expire
in 2026.
About RegeneRx Biopharmaceuticals, Inc. (www.regenerx.com)
RegeneRx is focused on the development of a novel therapeutic peptide,
Thymosin beta 4, for tissue and organ protection, repair and
regeneration. RegeneRx currently has three drug candidates in clinical
development for ophthalmic, cardiac and dermal indications, three
strategic licensing agreements in China, Pan Asia (Korea, Japan, and
Australia, among others) and the EU, and has an extensive worldwide
patent portfolio covering its products. The Company also has developed
several peptides that it believes may be useful improving aging skin in
the cosmeceutical field.
Forward-Looking Statements
Any statements in this press release that are not historical facts are
forward-looking statements made under the provisions of the Private
Securities Litigation Reform Act of 1995. Any forward-looking statements
involve risks and uncertainties that could cause actual results to be
materially different from historical results or from any future results
expressed or implied by such forward-looking statements. There can be no
assurance that any issued patents or licenses held by the Company or
patent applications filed by the Company will result in future value.
Please view these and other risks described in the Company’s filings
with the Securities and Exchange Commission (“SEC”), including those
identified in the “Risk Factors” section of the annual report on Form
10-K for the year ended December 31, 2013, and subsequent quarterly
reports filed on Form 10-Q, as well as other filings it makes with the
SEC. Any forward-looking statements in this press release represent the
Company’s views only as of the date of this release and should not be
relied upon as representing its views as of any subsequent date. The
Company specifically disclaims any obligation to update this
information, as a result of future events or otherwise, except as
required by applicable law.
Copyright Business Wire 2014